Rigel Pharmaceuticals (RIGL) Revenue (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Revenue of $58.8 million for Q1 2026, up 10.28% year-over-year from $53.3 million in Q1 2025, and down 15.74% quarter-over-quarter from $69.8 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Revenue (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Revenue history runs 16 years deep, the most recent figure standing at $58.8 million for Q1 2026.
- In Q1 2026, Revenue rose 10.28% year-over-year to $58.8 million; the TTM figure through Mar 2026 stood at $299.8 million (up 47.61% YoY), while the FY2025 annual figure was $294.3 million, up 64.15% from the prior year.
- Revenue for Q1 2026 stood at $58.8 million, down from $69.8 million in the prior quarter.
- The five-year high for Revenue was $101.7 million in Q2 2025, with the low at $16.7 million in Q1 2022.
- The 5-year median for Revenue is $36.8 million (2024), against an average of $45.3 million.
- The sharpest annual moves came in 2022 and 2025: Revenue slumped 79.34% in 2022, then jumped 176.01% in 2025.
- Rigel Pharmaceuticals' Revenue stood at $51.3 million in 2022, then slumped by 30.2% to $35.8 million in 2023, then soared by 60.92% to $57.6 million in 2024, then gained by 21.19% to $69.8 million in 2025, then slipped by 15.74% to $58.8 million in 2026.
- Business Quant data shows RIGL's Revenue at $58.8 million in Q1 2026, $69.8 million in Q4 2025, and $69.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 78.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78.70 Mn |
| Mar 31, 2026 | 58.82 Mn |
| Dec 31, 2025 | 69.80 Mn |
| Sep 30, 2025 | 69.46 Mn |
| Jun 30, 2025 | 101.69 Mn |
| Mar 31, 2025 | 53.33 Mn |
| Dec 31, 2024 | 57.60 Mn |
| Sep 30, 2024 | 55.31 Mn |
| Jun 30, 2024 | 36.84 Mn |
| Mar 31, 2024 | 29.53 Mn |
| Dec 31, 2023 | 35.79 Mn |
| Sep 30, 2023 | 28.13 Mn |
| Jun 30, 2023 | 26.89 Mn |
| Mar 31, 2023 | 26.07 Mn |
| Dec 31, 2022 | 51.28 Mn |
| Sep 30, 2022 | 22.41 Mn |
| Jun 30, 2022 | 29.82 Mn |
| Mar 31, 2022 | 16.74 Mn |
| Dec 31, 2021 | 20.41 Mn |
| Sep 30, 2021 | 21.54 Mn |